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A B S T R A C T
Peptidase inhibitors have an important role controlling a variety of biological processes. Here, we
employed a peptidomic approach including molecular cloning, tandem mass spectrometry and
enzymatic assays to reveal 7 Kazal-type proteinase inhibitors (CCKPs) (18 variants) in the skin secretion
of the unexplored frog, Cruziohyla calcarifer. All 18 proteins shared the Kazal pattern C-X(7)-C-X(6,7)-C-
X(6,7)-Y-X(3)-C-X(2)-C-X(15-21)-C and 3 disulphide bridges. Based on structural comparative analysis, we
deemed trypsin and chymotrypsin inhibitory activity in CCKP-1, 4 and CCKP 2, 5, 7, respectively. These
peptidase inhibitors presumably play a role to control the balance between other functional peptides
produced in the amphibian skin secretions.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Amphibian skin contains granular glands that are responsible
for synthesizing a complex mixture of different biologically active
peptides. Among these peptides are tachykinins, bradykinins,
sauvagines, caeruleins, bombesins, dermophins, dermaseptins,
and other peptides [1]. These peptides are synthetized as inactive
precursors often containing a signal peptide, an acidic spacer, and
the mature sequence. In addition, they usually have one or more
predicted processing sites within the acidic spacer, such as lysine-
arginine (KR) or two arginines (RR), which are a target for
peptidases with trypsin-like speciﬁcity [2–4].
Peptidases are hydrolases that are crucial in controlling a
variety of biological process, such as digestion, blood clotting,
wound healing, and host defence; but they are also involved in
pathogenic infection, viral replication, and disease progression
[5–7]. Besides, proteolytic enzymes play and important role in
releasing active mature peptides upon the surface of the frog, and
for this reason these enzymes must be carefully controlled. Among
the processes that could be involved in their control are spatial and
temporal regulation, zymogen activation, peptidase degradation,
and macromolecular peptidase inhibitors. However, these mecha-
nism have not been proven in amphibians up to now [5–12].
Peptidase inhibitors as well as peptidases are ubiquitous in
nature. Due to the fact that peptidase inhibitors show a high level
of homology in their active sites, they can inhibit multiple
peptidases at a rate of 1:5. The mechanism of inhibition in the
majority of peptidase inhibitors is competitive, interacting with
the active site of the peptidase in a substrate-like manner [6].
Proteinase inhibitors of different families and speciﬁcities have
been found in some amphibian species. The ﬁrst proteinase
inhibitors were found in the skin secretions of ﬁve species of
bombinid toads, including the following trypsin/thrombin inhib-
itors: BSTI of Bombina bombina; BMSI1 and BMSI2 of B. micro-
deladigitora; BOTI of B. orientalis; BVTI of B. variegata; and BMTI of B.
maxima. They have 60 amino acids and masses between 6345 and
6446.56 Da. Noticeably, they all contain 10 cysteine residues
similar to the distribution pattern of the peptidase inhibitor of the
nematode worm, Ascaris suum. In addition, they share the reactive
centre motif -CDKKC-, and their Ki is in the range of 0.1–1 mM
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[8,9,13,14]. Another species, Rana areolata contains three peptidase
inhibitors: one trypsin inhibitor of 61 amino acids that also
contains the 10 cysteine residue motif (6751 Da) and is similar to
the protein inhibitor from A. suum; a 48 residue elaﬁn-related
peptide (of mass 5164 Da) with 8 cysteine residues distinctive for
whey acidic protein (WAP) motif; and a secretory leukocyte
peptidase inhibitor [15].
Other proteinase inhibitors found in amphibian skin secretions
can be classiﬁed based on the presence of their structural motifs such
as Kunitz, Bowman-Birk and Kazal types. Two Kunitz type proteinase
inhibitors have been isolated from Dyscophus guineti and Kassina
senegalensis. The ﬁrst is a trypsin inhibitor of 57 residues and
6301 Da, which belongs to the Kunitz/bovine pancreatic trypsin
inhibitor family; and the second a chymotrypsin inhibitor (KSCI) of
62 residues and 6776.24 Da, which is structurally similar to other
chymotrypsin inhibitors from silkworms to snakes. KSCI has its
P1 site occupied bya phenylalanine residue and contains 6 cysteines
that form 3 disulphide bridges [16,17].
The next group of proteinase inhibitors contain the Bowman-
Birk motif. They include the following trypsin inhibitors: HV-BBI
isolated from Odorrrana versabilis; HJTI isolated from O. hejian-
gensis; and pLR-HL isolated from Hylarana latouchii. These
inhibitors have 17–18 residues, their masses range between
1804.83 and 2013.95 Da, and their Ki varies between 19 and
388 nM. Besides, they share a disulphide loop between 2 cysteines
spaced by 9 residues, and have a lysine in the third position inside
the loop, which corresponds to the P1 site of the inhibitor [18,19].
In addition, OGTI isolated from O. grahami, is another trypsin
inhibitor similar to those described above. OGTI contains 17 amino
acids and its molecular mass is 1949.4 Da. However, OGTI contains
a smaller disulphide loop formed by 2 cysteines that are 4 residues
apart, and it has a lysine in the P1 site as the immediate residue
following the ﬁrst cysteine [20].
Finally, Kazal-type protein inhibitors seem to be more taxa-
speciﬁc. Until now, they have only been reported in the
Phyllomedusinae clade. Two prolyl endopeptidase inhibitors,
PSKP-1 and PSKP-2 of 58 residues and 6695.87 and 6548.65 Da,
respectively, have been isolated from Phyllomedusa sauvagii. PSKP-
1 and PSKP-2 share two prolines in the P1 and P2 positions of the
putative active sites, making them unable to inhibit trypsin,
chymotrypsin, v8 peptidase, and proteinase K [21]. In contrast,
ACKTI of 5892.82 Da – a trypsin inhibitor isolated from Agalychnis
callidryas – has proline in P2 but arginine in the P1 position
consistent with other trypsin inhibitors [22]. In addition, another
two Kazal-type peptidase inhibitors – PI01 and PI02–were
identiﬁed in P. nordestina by ETS analysis; however, their speciﬁcity
has not been elucidated [23].
Although the biological roles of the amphibian proteinase
inhibitors have not been established with certainty, they may
include defence against extrinsic peptidases produced by patho-
genic microorganisms to prevent damage of host tissue and
evasion of host defences. Proteinase inhibitors could also prevent
degradation of bioactive peptides, so they can target cell receptors.
In addition, proteinase inhibitors might act indirectly as regulators
of the processing reactions of bioactive peptides, including cationic
a-helical antimicrobial peptides, allowing them to be released
onto the skin, so they can display their activity and protect the skin
from invading microorganisms [8,9,16].
The present study was focused on the Splendid leaf frog,
Cruziohyla calcarifer, which belongs to the Phyllomedusinae clade—
a known source of pharmacological and antimicrobial peptides.
Recently, one insulin-releasing peptide RK-13, and 18 cruzioseptins
with antimicrobial activity have been described from C. calcarifer
[24,25]. Here, we describe a group of 7 peptidase inhibitors (with
18 variants) in C. calcarifer skin secretion which belong to the
Kazal–type family. One of these, CCKP-1, showed trypsin inhibitory
activity and possessed a lysine in its P1 site and unusually, an
asparagine in its P2 site. Based on their structural homology, it is
predicted that CCKP-2, CCKP-5 and CCKP-7 have chymotrypsin
inhibitory activity, while CCKP-4 has trypsin inhibitory activity.
Therefore, the proteinase inhibitors of Kazal-type from C. calcarifer
are the most diverse group of proteinase inhibitors found to date in
a single amphibian species.
2. Material and methods
2.1. Sourcing of samples
The skin secretions of Cruziohyla calcarifer employed in this
study came from two different geographical locations, Costa Rica
and Ecuador.
The ﬁrst Costa Rican sample consisted of a pool of two adults
secretions collected in 1999. While the Ecuadorian sample consisted
of a pool of four juvenile captive breed and one wild adult secretion
collected in 2013. The four juvenile captive bred frogs (n = 4) (from
Esmeraldas Province, Reserve Otokiki) were provided by Centro
Jambatu for Research and Conservation of Amphibians in Ecuador
and the wild specimen of Cruziohyla calcarifer (n = 1) was collected in
northwestern Ecuador (Esmeraldas Province, Durango). Skin
secretions were extracted from each frog by lightly stressing the
animal – massaging the dorsal area of the frog – thenwashing off the
secretion with distilled water. Secretions from the same geographi-
cal location were pooled, equally split into two 50 mL conical tubes,
and then freeze dried. Samples were transported to Queen’s
University Belfast at room temperature and dried samples were
stored at 20 C prior to their analysis.
Moreover, twelve additional samples were extracted from a
group of 13-month-old captive bred frogs in 2015. The parental line
of these frogs came from a Costa Rican population and the animals
were housed in terraria as pets in Belgium and Austria. Skin
secretions were extracted in the same way as described above but
kept individually. In contrast to the previous samples, the twelve
samples were acidiﬁed with TFA and transported at room
temperature to the laboratory facilities in Queen's University
Belfast where they were freeze-dried.
Collection and rearing of frogs in Ecuador and transportation of
samples were done under permits of the Ecuadorian Ministerio de
Ambiente (MAE) (described in acknowledgments).
2.2. Molecular cloning
One aliquot containing half of the dried secretion material of the
Ecuadorian sample was dissolved in 1 mL of cell lysis/binding buffer
and polyadenylated mRNA was isolated using magnetic Dynabeads
Oligo (dTs), as described by the manufacturer (Dynal Biotec, UK).
Isolated mRNA was subjected to 30-rapid ampliﬁcation of cDNA by
using the SMART-RACE kit (Clontech, UK). Brieﬂy, the 30-RACE
reaction used a nested universal primer (NUP), provided with the kit,
and two senses primers: S1: 50-AGCAGCAAAAGAAGAAGAAGCCATG-
30 and S2: 50- GAGAAGAAGCCATGAAGACTCTGA-30, that were
complementary to the signal sequence of the ACKTI gene precursor
of Agalychnis callidryas. The 30-RACE product was puriﬁed and
cloned using a pGEM-T vector system (Promega Corporation), and
latersequenced using an ABI 3100 automated sequencer. Nucleotide
sequences were analysed with MEGA 6.0 and Vector NTI software
(Life technologies) [26]. Sequences were compared with databases
in the NCBI using the BLAST tool [27]. Theoretical peptide masses
were calculated with the peptide mass calculator 3.2 and secondary
structure was predicted with GOR IV method [28,29]. Nucleotide
sequences were submitted to the GenBank of the NCBI, accession
numbers are included in Table 1.
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2.3. Reverse phase HPLC fractionation of skin secretion
Different experimental conditions were necessary for the
separations as follow:
The Ecuadorian sample (remaining half of the dried secretion)
was dissolved in 1.2 mL of solution A (99.95% H2O, 0.05%
triﬂuoroacetic acid) and clariﬁed by centrifugation. 1 mL superna-
tant was subjected to reverse phase HPLC employing a Waters
binary pump HPLC system ﬁtted with an analytical column:
Phenomenex Jupiter C-18 (4.6  250 mm). Peptides were eluted
with a gradient formed from 100% solution A (99.95% H2O, 0.05%
triﬂuoroacetic acid) to 100% solution B (80.00% acetonitrile, 19.95%
H2O, 0.05% triﬂuoroacetic acid) for 240 min at a ﬂow rate of 1 mL/
min. Fractions of 1 mL were collected every minute. Detection at
214 and 280 nm was performed continuously.
The Costa Rican sample (0.5 mL of 3 mL) from 1999 was injected
onto an HPLC system ﬁtted with a semi-preparative C-18
Phenomenex Jupiter Column employing a gradient of 0–80%
solution B for 80 min at a ﬂow rate of 2 mL/min. Fractions were
collected every minute. This analysis was performed on 08/03/
1999.
2.4. MALDI-TOF MS
The molecular masses of peptides and proteins in each
chromatographic fraction were analysed by matrix-assisted laser
desorption/ionization time of ﬂight mass spectrometry (MALDI-
TOF MS) using a linear time of ﬂight Voyager DE mass spectrometer
(Perseptive Biosystems, MA, USA). First, the instrument was set in
positive detection mode and all fractions were analysed with
a-cyano-4-hydroxycinnamic acid (CHCA) matrix (10 mg/mL) for
low mass peptides. The settings of the instrument were as follows:
mode of operation: linear, accelerating voltage: 2000 V, acquisition
mass range: 500–5000 Da, number of laser shots: 50/spectrum,
laser intensity: 1813. Later, fractions were analysed for high mass
proteins employing sinapinic acid (10 mg/mL) as matrix. The
settings of the instrument were as follow: mode of operation:
linear, accelerating voltage: 25000 V, acquisition mass 500–
10,000 Da, number of laser shots: 50/spectrum, laser intensity:
3119. In both cases, two microliters of sample plus 1 mL of matrix
(10 mg/mL) were allowed to dry and later analysed for mass/
charge.
2.5. MS/MS sequencing
20 mL of the remaining skin secretion of the Ecuadorian sample
dissolved in solution A were applied directly to an analytical HPLC
column (Phenomenex C-18; 4.6  150 mm) connected to a linear
ion-trap mass spectrometer (LCQ-Fleet, Thermo Fisher). The linear
elution gradient was formed from 100% solution A (99.90% H2O,
0.1% formic acid) to 100% solution B (80% acetonitrile, 19.0% H2O,
0.1% formic acid) for 135 min at a ﬂow rate 20 mL/min. The mass
spectrometer was controlled by Xcalibur software (Thermo). The
mass analysis was performed in positive ion mode, and the
acquired spectra were in the range of m/z 500–2000 Da. The
parameters for electrospray ionization ion-trap mass spectrometry
(ESI/MS) were: spray voltage +4.5 kV, drying gas temperature
320 C, drying gas ﬂow 200 mL/min, and maximum accumulation
time – for the ion trap – 350 ms. After the ﬁrst mass analysis in full
scan mode, peptide ions with >50% relative intensity were
fragmented by collision induced dissociation (CID), in order to
generate b and y ions that were detected in a second mass analysis.
Fragment ion proﬁles were analysed by Proteome Discoverer 1.0
software (Thermo). In order to conﬁrm the amino acid sequences
of individual peptides we used the SequestTM algorithm which
compares the acquired fragment ion proﬁles with the theoreticalTa
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fragment ions generated from a FASTA ﬁle containing the speciﬁc
sequences obtained by molecular cloning of this species.
In addition, twelve individual samples from the Costa Rican
population were analysed in the same way as described above but
instead of 135 min these samples were run for only 120 min.
2.6. In solution Trypsin digestion
The HPLC fraction 91 was freeze-dried and later reconstituted in
5 mL of Solution A (99.95% H2O; 0.05% TFA). The sample was
denatured with 8 M Urea, 25 mM Tris and 20 mM DTT (ﬁnal
concentrations) and incubated at 60 C for 1 h. The alkylation of the
sample was performed with Iodoacetemide (IAA) at 40 mM and
A) CC KP-1
M   K   T  L   I  S  S   A  L  L  F    C  I  L 
1 GAAG AAGC CA T GAAG ACTC T GATCTCCTCC G CCTTG CTCT TCTGTATAC T
A  A   A   L  W  P  V   P  E  A   E  G   A   V  S  A E
51 GGCA GCAG CA T TGTG GCCG G TTCCTGAAGC A GAAGG TGCA GTTTCGGCA G
C  A  R    Y   G  L   A  C  N  K   M  L  A   P   V  C  
101 AATG CGCC CG C TATG GTCT G GCCTGCAACA A AATGT TAGC ACCTGTTTG T
G  T  D  G   T  T   Y   S  N  Q   C  M  L  C   Y  Y   N 
151 GGAA CTGA TG G AACG ACAT A CTCCAACCAG T GCATG CTGT GCTACTATA A
R  K  N   K K   N   I   E  I  R   S  R  G   R  C  *
201 CAGA AAAA AT A AGAA GAAT A TTGAAATTAG G TCAAG GGGT CGATGCTGA G
251 GAAG TCGT AT T AGAT CCCG G AGAGCTTCAG A CACCG ATGT TCTGTGAAG T
301 GATG ATTA CG G CAAA AGAA A AATCAATGAC A TGAAA AATA AATCCTGTG C
351 AATC CAAT GT C CAGACATGT TACAATAAAG A GTGGA AGCC TTATA AAAA A
401 AAAA AAAA AA A AAAA AAAA A
B) CC KP-2
M  K   T   L  I  S   S  A  L   L  F  C  I   L  A  A 
1 GCCA TGAA GA C TCTG ATCT C CTCCGCCTTG C TCTTC TGTA TACTGGCAG C
A  L  W   P  V  P   E   A  E  G  A  T  E   P  D  C   K
51 AGCA TTGT GG C CAGT TCCT G AAGCAGAAGG T GCAAC TGAG CCAGACTGT A
K  Y   P   G  K  C   P  L  A  Q   N  P   V   C  G  T
101 AGAA GTAT CC G GGGA AATG T CCTTTAGCTC A AAATC CTGT GTGTGGAAC A
D  G  R  M   Y  Y N   E  C  A   L  C  V  F   M  R   D 
151 GATG GAAG AA T GTAC TACA A TGAGTGCGCG C TGTGC GTCT TTATGAGGG A
S  K  N   K  V  K   I   Q  I  K   K  M  G   K  C  *
201 CAGT AAGA AT A AAGT TAAA A TTCAAATTAA A AAAAT GGGT AAATGCTGA A
251 GAGC TCGT AT T AAAT CCTG G AGAGCTTCAG A CACCG ATGT TCTGCAAAG T
301 GATG ATAA AA A CAGC GAAT A AAAAATCAAT G ACATG AAAA ATAAATCCT G
351 TGCA ATCC AA T GTCC AGAC A TGTTACAATA A AGAGT GGAA GCCTTGATC T
401 GTAG CAAC AA A AAAA AAAA A AAAAAAAAAA A AA
C) CC KP-3
M  K  T  L   I  S   S   V  L  L F  C  I  L   A  A   A 
1 ATGA AGAC TC T GATC TCCT C CGTCTTGCTC T TCTGT ATAC TGGCAGCAG C
L  W   P   V  P  K  A   E  G A   T  K  P   K  C  P   S
51 ATTG TGGC CA G TTCC TAAA G CAGAAGGTGC A ACTAA GCCG AAATGTCCC T
L  F  S    S   G  C   P  S  T  Q   D  F  V C   G  T
101 CCCT GTTT TC C TCAG GGTG C CCCAGTACAC A AGATT TTGT TTGTGGAAC A
D  G  N  S   Y  M   N   E  C  V   M  C  K  M   N  K   N 
151 GATG GAAA TT C ATAC ATGA A TGAGTGCGTG A TGTGC AAAA TGAACAAGA A
N  G   G   K  V  K  V   V  K  K   G  Y   C  *
201 CAAT GGGG GA A AGGT TAAG G TTGTAAAAAA G GGATA CTGC TGAGAAGCT C
251 ATAT TAAA TC C TGGA GACA C CGATGTTCTG T GAAGT GATG ATTACAGCA A
301 AAGG AGAA TT A ATCA AATG A AAATTCCTGT G CAATC CAAT GTCCAGACA T
351 GTTA CAAT AG A GAGT GGAA G CCTTGATCTG T AACAA AAAA AAAAAAAAA A
401 AAAA AAAA AA  A
Fig. 1. Nucleotide and translated open-reading frame amino acid sequences of cloned cDNAs that encode the biosynthetic precursors of the Kazal-type proteins from
Cruziohyla calcarifer. A–G) Representative seven types of Kazal-type proteins with a range of 51–73 amino acids. The putative signal peptides are double-underlined, the
mature sequences are single-underlined and the stop codons are indicated by asterisks.
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incubated in dark at room temperature for 30 min. The alkylation
reaction was quenched with DTT solution at 10 mM (ﬁnal
concentration). Later, the sample was diluted 10 times with
200 mM ammonium blcarbonate and digested with 0.5 mL of
trypsin solution (1 mg/mL) at 37 C for 8 h. The digestion reaction
was stopped by adding 10 mL of 2.5% TFA solution and then cleaned
up with C18 ZipTip. In brief, the trypsin-digested sample was
drawed to a previously wet C18 ZipTip at least 10 times. Then, the
ZipTip was washed with 20 mL of 0.1% TFA for three times. Tryptic
fragments were eluted with 20 mL of 80% ACN/0.1% TFA by
pipetting up and down for 10 times. Ten microliter of eluted
fragments were subjected for LC–MS/MS analysis as described
above.
2.7. Trypsin inhibitor assay
HPLC fractions (400 mL), containing proteins with molecular
masses higher that 5 kDa, were dried in a vacuum concentrator.
M  K   T  L  I   S  S  A   L  L  F  C   I  L A  
1 GAAG CCAT GA A GACT CTGA T CTCCTCCGCC T TGCTC TTCT GTATACTGG C
A  A   L   L  P  V  L   E  A G    G  V   V   L  L  D C
51 AGCA GCAT TG T TGCC GGTT C TTGAAGCAGG A GGTGT AGTT CTGCTGGAC T
R  P   Y   G  P  V   C  S  K  I   F  D   P   V  C  G
101 GCCG CCCG TA T GGCC CAGT T TGCAGCAAAA T ATTTG ATCC TGTTTGTGG A
T  N  F  I   T  Y   D   N  T  C   E  L  C  K   A  Q   R 
151 ACAA ATTT CA T AACA TATG A CAATACGTGC G AGCTG TGCA AGGCACAAA G
E  N   P   R  I  S  M   R  T  K   G  K   C  *
201 AGAG AATC CG A GGAT TAGT A TGAGAACTAA A GGTAA ATGC TGATGGAAG T
251 TGTA TCAG AT C CCGG AGAG C TTCAGACGCT G ACTTT TCTT TTGCCAAAG T
301 CATC GTTT CA G TTAC ATGT A AAATAAACCC T GTGCA ATCC AATGTCCAG A
351 CATG TTCC AA TAAAG AGTGG AAGCCTTGAT C TGCAA AAAA AAAAA AAAA A
401 AAAA AAAA A
E) CC KP-5a
M  K  T   L  I  S  S   V  L   L 
1 GCAG CAAA AG A AGAA GAAG C CATGAAGACT C TGATC TCCT CCGTCTTGC T
F  C  I   L  A   T  A   L  W  P   I  H  E   A  E  A  V 
51 CTTC TGTA TA C TGGC AACA G CATTGTGGCC A ATTCA TGAA GCAGAAGCT G
I  E   P   N  C  K   K  Y  E  G   K  K   C   D  L  N
101 TAAT TGAG CC A AACT GTAA G AAGTATGAGG G AAAAA AGTG TGATCTAAA C
P  N  P  V   C  G   T   N  G  R   E  Y  F  N   E  C   A 
151 CCAA ATCC TG T TTGT GGAA C AAATGGACGA GAATAC TTCA ATGAGTGCG C
L  C  V   F  I  R   D   S  K  K   K  A  D   K  M  V   K 
201 GCTG TGCG TC T TTAT CAGG G ACAGTAAGAA G AAAGC TGAT AAGATGGTT A
I  K   K   W  G  K   C  *
251 AAAT TAAA AA A TGGG GTAA A TGCTGAGGAG C TCATA ATAA ATCCTGGAG A
301 GCTT CAGA CA C CGAT GTTC T GTGAAGTGAT G ATTAC AGCA AAAGAAAAA T
351 CAAT CAGA TG A AAAA TAAA T CCTGTGCAAT C CAATG TCCA GACATGTTA C
401 AATA AAGA GT G GAAG CCTT A AAGAAAAAAA A AAAAA AAAA AAAAAAAAA A
F) CC KP-6a
M  K   T  L  I   S  S  A   L  L  F  C  I  L   A 
1 GAAG CCAT GA A GACT CTGA T CTCCTCCGCC T TGCTC TTCT GTATACTGG C
A  A  L   W  P  I   P   E  V  E   G E   E   D  V  A   C
51 AGCA GCAT TG T GGCC AATT C CTGAAGTAGA A GGTGA AGAA GATGTGGCC T
P  W   Y   Y  V  F   G  C  H  D   K  Y   T   V  C  G
101 GTCC TTGG TA T TACG TGTT T GGGTGCCACG A CAAAT ACAC TGTTTGTGG A
T  D  G  V   T  Y   P   N  K  C   T  L  C  K   I  N   G 
151 ACAG ATGG AG T CACA TACC C CAATAAATGC A CCCTG TGCA AGATAAATG G
E  D  N   I  K  I   R   K  W  G   N  C  *
201 AGAG GACA AC ATTAA AATTA GAAAATGGGG T AACTG CTGA GGAGC CCGT A
251 TTAA ATCT TG T AAAG CTTC A GACGCTGAAA T ATTTT GCTA CGTGATAAT G
301 AAGG CAAT AG A AAAA TCAA T CAGATGAAAA A TAAAC CCTG TGCAATCCA A
351 TGTA CAGA CA T GTTA CAAA A AAGAAAAAAA A AAAAA AAAA AA
D) CC KP-4a
Fig. 1. (Continued)
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Fractions were reconstituted in 22 mL of PBS and screened for
trypsin inhibition. In brief, 180 mL of substrate working concentra-
tion (50 mM Z-Gly-Gly-Arg-AMC) were placed in 4 rows of a black
96-well plate. Then, 10 mL of each fraction were placed in the plate
in duplicates and the ﬁrst 5 cycles of ﬂuorescence were measured
to establish a baseline. Next, 10 mL of trypsin solution (0.001 mg/
mL) were added to each well, excepting the ﬁrst two that
constituted negative controls and contained only substrate. The
next two columns contained substrate and trypsin as positive
controls. Finally, hydrolysis of the substrate by trypsin was
monitored by the ﬂuorescence generated for 60 min employing
a Fluostar Optima plate reader (BMG LABTECH spectroﬂuorimeter)
set to 460 nm emission and 395 nm excitation.
2.8. Chymotrypsin inhibition assay
The chymotrypsin inhibition assay was performed in the same
way as the trypsin inhibition assay described previously with the
following differences: the substrate Suc-Ala-Ala-Pro-Phe-AMC
(50 mM), and chymotrypsin solution (0.001 mg/mL) were
employed for this assay.
3. Results
3.1. Molecular cloning of Kazal protein precursor encoding cDNA
A group of 7 novel Kazal-type proteins (18 variants) with
proteinase inhibitory activity was identiﬁed by molecular cloning
of the skin secretion of Cruziohyla calcarifer. Their nucleotide and
translated amino acid sequences are described in Fig. 1. The
translated open reading frames of these precursors contain 76 to
93 amino acids. The ﬁrst 24–26 residues constitute a putative
signal peptide, predicted by the SignalP 4.0 server, while the
remaining 51–73 amino acids correspond to the mature Kazal-type
inhibitor protein (Fig. 2). Table 1 shows the sequences of the
18 different variants found within these Kazal proteinase inhibitors
and their theoretical average masses fall in the range of 5782–
8392 Da. In addition, all seven Kazal-types proteins and their
variants share the Kazal pattern C-X(7)-C-X(6,7)-C-X(6,7)-Y-X(3)-C-
X(2)-C-X(15-21)-C, as highlighted in Table 2. Proteins were labelled
Cruziohyla calcarifer Kazal Protein 1-7 (CCKP-1-7) adding letters for
their variants. Sequences were submitted to GenBank (NBCI) with
accession numbers: KX065060–KX065077.
3.2. Identiﬁcation, isolation, and structural characterization of the
trypsin inhibitory Kazal-type protein
The HPLC fractions of the Costa Rican population obtained in
1999 were analysed by MALDI-TOF mass spectrometry in 2013, and
all fractions containing m/z peaks between 5 and 8 kDa were
selected. The selected fractions were: 29–33. Each fraction was
tested for trypsin and chymotrypsin inhibitory activity, however
only fractions # 32 and 33 showed trypsin inhibitory activity
(Fig. 3). MALDI-TOF mass spectrometric analysis of trypsin
inhibitor fractions: #32 and 33 revealed a singly-charged ion of
m/z 5926.43 that was conﬁrmed by LCQ analysis (data not shown).
This mass was consistent with the sequence of CCKP-1 (Table 1 and
Fig. 4).
Recently, the Ecuadorian sample of Cruziohyla calcarifer skin
secretions was fractionated by reverse phase HPLC for 240 min, and
they were found to be a complex mixture of different peptides due
to the numerous peaks observed in the chromatogram at 214/
L  C  I   L  A  T   A   L  A  P   L  P  S   Q  P  Q   F
51 CCTC TGTA TA C TGGC AACA G CATTGGCGCC G CTTCC TTCT CAACCTCAA T
F  K   K V  L  K   T  L  A  E    P  N   C   K  K  Y
101 TTTT CAAG AA G GTTC TTAA A ACTCTAGCTG A GCCAA ACTG TAAGAAGTA T
E  G  K  K    C   D  L   N  L  N   P  V  C  G   T  N  G 
151 GAGG GAAA AA A GTGT GATC T AAACCTAAAT C CTGTG TGTG GAACAAATG G
R  T  Y   Y  N  E   C   A  L  C   V  F  I   R  D  S   T 
201 AAGA ACGT AC T ACAA TGAG T GCGCGCTGTG C GTCTT TATC AGGGACAGT A
K  K   S   D  K  M   V  K  I  H   K  W   G   K  C  *
251 CGAA GAAA TC T GATA AGAT G GTTAAAATAC A TAAAT GGGG TAAATGCTG A
301 GGAG CTCA GA A TAAA TCCT G GAGAGCTTCA GACACC GATG TTCTG TGAA G
351 TGAT GATT AC A GCGA AAGA A GAATCAATCA G ATGAA AAAT AATCCAATG T
401 CCAG ACAT GT T CCAA TAAA G AGTGGAAGCC T TGATC TGTA ACACAAAAA A
451 AAAA AAAA AA A AAAA AAA
G) CC KP-7a
M  K  T   L  I  S  S   V  L  L 
1 GCAG CAAA AG A ATAA GAAG C CATGAAGACT C TGATC TCCT CCGTCTTGC T
Fig. 1. (Continued)
Fig. 2. Precursor structures of Kazal-type proteins from Cruziohyla calcarifer. All amino acid sequences contain a signal peptide (19–26 residues)-predicted by the
SignalP4.1 server, followed by the mature sequence (51–73 residues).
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280 nm (Fig. 5). Besides, it was also noticeable that these peaks
were very low compared to other chromatograms obtained in our
research group that were 8 times higher. Usually 5–10 mg of dried
secretion is employed for HPLC fractionation; however, the
secretions of C. calcarifer were very scarce and could not be
weighed. MALDI-TOF analysis was performed on each fraction and
those fractions containing peptides with high molecular mass
(5–8 kDa) were analysed for proteinase inhibitory activity (trypsin
and chymotrypsin inhibition). The fractions tested were #81–85,
109, 110, 121–127, and 129; however, only fractions # 81–85
showed trypsin inhibition (Fig. 3). MALDI TOF MS analysis and LCQ
MS conﬁrmed a mass of 5953 Da that did not coincide with any of
the sequences found by molecular cloning to date. As a
consequence of the initial low amount starting material, it was
not possible to determine the Ki value of these peptidase
inhibitors.
In addition, we analysed 13 skin secretion samples (1 Ecua-
dorian and 12 Costa Rican samples) directly by tandem mass
spectrometry. By using Sequest algorithm, we conﬁrmed the 100%
coverage of amino acid sequences of the 18 variants of Kazal type
proteins initially found by molecular cloning (Table 1 include the
best scores of these analysis). Moreover, the fraction 91 was trypsin
digested and later analysed by LC–MS/MS which conﬁrmed the
sequence of CCKP-7b (Fig. 6).
3.3. Bioinformatic analyses on Kazal-type proteinase inhibitors
The Kazal motif was identiﬁed in the 7 novel proteins and
18 variants of Cruziohyla calcarifer by BLAST analysis using
databases from the NCBI.
The precursor sequence of Cruziohyla calcarifer Kazal protein-1
(CCKP-1) was compared with NCBI databases (BLAST/n tool), and it
showed 76% similarity with the trypsin inhibitor, ACKTI, of
Agalychnis callidryas (accession number HE653907.1). However,
the translated mature protein only shared 52–55% similarity with
trypsin inhibitor proteins from the fulmar Fulmarus glacialis, the
falcon Falco cherrug, the egret Egretta garzetta, and A. callidryas
(accession numbers: XP_009582735.1,XP_005436761.1,
XP_009633154.1, and CCF72386.1 respectively) (Table 3). Subse-
quent bioinformatic analysis of the CCKP-1 predicted secondary
structure showed additional similarities with the pancreatic
secretory trypsin inhibitor of the salmon Salmo salar and the
trypsin inhibitor of the boar Sus scrofa, especially at their C-
terminal sites, as shown in Fig. 7.
The mature sequence of Cruziohyla calcarifer Kazal protein-2
(CCKP-2) displayed 66–68% similarity with the proteinase
inhibitors: PSKP-1 and PSKP-2 of Phyllomedusa sauvagii; and
PI01 and PI02 of P. nordestina (accession numbers: P83579.2,
P83578.1, AFY11406.1, and AFY11405.1 respectively). In addition,
CCKP-2 was 47% similar to the chymotrypsin inhibitor from the
tinamou Tinamus guttatus (accession number KGL85187.1). More-
over, its secondary structure was similar to the chymotrypsin
inhibitor of the penguin Pygoscelis adeliae, especially in its
N-terminal region (see Fig. 8).
The mature sequence of Cruziohyla calcarifer Kazal protein-3
(CCKP-3) revealed 53–55% similarity with the pancreatic secretory
trypsin inhibitor of the frog Xenopus (Silurana) tropicalis; the serine
peptidase inhibitor Kazal-type 2 of the cormorant Phalacrocorax
Table 2
Alignment of the mature sequences of Kazal proteins indicating the canonical Kazal motif.
Protein Matu re pept ide
I II III IV V VI
* * * * * * * * * *
CCKP-1 (7) - - A V S A E C A - R Y G L A C N K M L A P V C G T D G T T Y S N Q C M L C Y Y N R K N K K N - - - - I E I R S R G R C
CCKP-2 (8) - - A T E P D C K K Y P G - K C P L A Q N P V C G T D G R M Y Y N E C A L C V F M R D S K N K V K - - I QI K K M G K C
CCKP-3 (7) - - A T K P K C P S L F S S G C P S T Q D F V C G T D G N S Y M N E C V M C K M N K N N G - - - - G K V K V V K K G Y C
CCKP-4a  (1) G G V V L L D C R - P Y G P V C S K I F D P V C G T N F I T Y D N T C E L C K A Q R E N P R - - - - - I S M R T K G K C
CCKP-4b  (1) - - V V R L D C R - P Y G P V C S K I F D P V C G T N F I T Y D N T C E L C K A Q R E N P R - - - - - I S M R T K G K C
CCKP-4c (1) - - V V R L D C R - P Y G P V C S K V L D P V C G T N F K T Y D N T C E L C K A Q R E N P R - - - - - I S M R T K G D C R K P Y L I P E N F R R
CCKP_5a (4) - - V I E P N C K K Y E G K K C D L N P N P V C G T N G R E Y F N E C A L C V F I R D S K K K A D K M C K I K K W G K C
CCKP_5b (2) - - V I E P N C K K Y E G K K C D L N P C P V C G T N G R E Y Y N E C A L C V F I R D S K K K A D K M V K I K K W G K C
CCKP_5c (3) - - V I E P N C K K Y E G K K C D L N P N P V C G T N G R E Y F N E C A L C V F I K D S K K K A D K M V K I K K W G K C
CCKP_5d (1) - - V I E P N C K K Y E G K K C D L N P N P V C G T N G R E Y F N E C A L C V F I R D S T K K A D K M V K I K K W G K C
CCKP_6a (1) - - E E D V A C P W Y Y V F G C H D - K Y T V C G T D G C T Y P N K C T L C K I N G E D - - - - - - N I K I R K W G N C
CCKP_6a (2) - - E E D V T C P W Y Y V F G C H D - K Y T V C G T D G V T Y P N K C T L C K I N G E D - - - - - - N I K I R K W G N C
CCKP_7a (5) P L P S Q P Q F F K K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G R T Y Y N E C A L C V F I R D S T K K S D K M V K I H K W G K C
CCKP_7b (1) P P P S Q P Q F S N K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G R T Y Y N E C A L C V F I R D S T K K A D K M V K I H K W G E C
CCKP_7c (1) P L P S Q P Q F F K K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G R T Y Y N E C A L C V F I R N S T K K S D K M V K I H K W G K C
CCKP_7d (1) P L P T Q P Q F F K K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G R T Y Y N E C A L C V F I R D S T K K S D K M V K I H K W G K C
CCKP_7e (2) P L P S Q P Q F F K K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G G T Y Y N E C A L C V F I R D S T K K S D K M V K I H K W G K C
CCKP_7f (1) P L P S Q P Q F S D K V L K T L A E P N C K K Y E G K K C D L N L N P V C G T N G R T Y Y N E C A L C V F I R D S T R K A D K M V K I H K W G K C
Kazal patt ern C C P2 P1 C Y C C C
Pred icted  disulfide  bond s
*Conserved sites, (x) number of clones with the same sequence. The Kazal motif is highlighted: 6 Cysteines are in yellow, one Tyrosine in pink, and P1 and P2 sites in red.
Conectors indicate predicted disulﬁde bond formation.
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Fig. 3. Trypsin inhibitory activity of HPLC fractions. A) Fractions 32–33 from the
Costa Rican sample. B) Fractions 81–85 from the Ecuadorian sample.
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carbo; and the trypsin inhibitor CITI-1 of the ostrich Struthio
camelus australis (accession numbers: XP_002939857.1,
XP_009500666.1, and KFV85841.1 respectively).
The mature sequences of Cruziohyla calcarifer Kazal protein-4
(CCKP-4a, CCKP-4b, and CCKP-4c) showed 45–52% similarity with
the sperm-activating protein of the herring Clupea pallasii, the
pancreatic secretory trypsin inhibitor of Salmo salar, and the serine
peptidase inhibitor Kazal-type 12-like of the shrew Tupaia
chinensis (accession numbers: BAA14009.1, NP_001140094.1, and
XP_006148122.1 respectively).
The mature sequences of Cruziohyla calcarifer Kazal Protein-5
(CCKP-5a, CCKP-5b, CCKP-5c, and CCKP-5d) and C. calcarifer Kazal
protein-7 (CCKP-7a to CCKP-7f), similarly to CCKP-2, exhibited 64–
78% similarity with proteinase inhibitor PSKP1 and PSKP-2 of
Phyllomedusa sauvagii; and proteinase inhibitors PI01 and PI02 of P.
nordestina (accession numbers: P83579.2, P83578.1, AFY11406.1,
and AFY11405.1 respectively).
Finally, the mature sequences of Cruziohyla calcarifer Kazal
protein-6 (CCKP-6a and CCKP-6b) revealed 48–52% similarity with
the serine peptidase inhibitor Kazal-type 2 from the cuckoo
Cuculus canorus; the pancreatic secretory trypsin inhibitor-like
from the lizard Anolis carolinensis; and the trypsin inhibitor CITI-1-
like of the bird Cariama cristata (accession numbers:
XP_009565924.1, XP_008118717.1, and XP_009700547.1 respec-
tively).
4. Discussion
Peptidase inhibitors with three different motifs – Kunitz,
Bowman-Birk and Kazal – have been previously identiﬁed in some
amphibians; however, Kazal-type inhibitors appeared to be
speciﬁc to Phyllomedusinae. Among them are: the Kazal prolyl
endopeptidase inhibitors PSKP-1 and PSKP-2 isolated from
Phyllomedusa sauvagii; the proteinase inhibitor PI01 and
PI02 from P. nordestina; and the trypsin inhibitor ACKTI isolated
from Agalychnis callidryas [18–20]. Here, we report the ﬁnding of a
group of seven distinguishable Kazal-type proteinase inhibitors in
Cruziohyla calcarifer with 18 variants (Table 1). NCBI Database
interrogation using the amino acid sequence of the mature
proteins identiﬁed the Kazal motif C-X(7)-C-X(6,7)-C-X(6,7)-Y-X(3)-
C-X(2)-C-X(15-21)-C in all 7 Kazal-type proteins and in their
18 different variants (Table 2).
It was found that the CCKP-1 nucleotide sequence was 75%
similar to the precursor of the trypsin inhibitor Kazal-type of
Fig. 4. MALDI-TOF MS spectrum of HPLC fraction 32 with trypsin inhibitory activity. The arrow denotes CCKP-1 with a molecular mass of 5926.43 Da.
Fig. 5. Reverse phase HPLC chromatogram of skin secretion from Cruziohyla calcarifer fractionated over 240 min. The arrow denotes fractions 81–85 showing trypsin
inhibitory activity. Detection at 214 nm (red line) and detection at 280 nm (green line).
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Fig. 6. Tryptic fragments sequenced by tandem mass spectrometry corresponding to the Cruziohyla calcarifer Kazal protein 7b (CCKP-7b). A) Sequence coverage of tryptic
fragments, B–D) MS/MS proﬁles of the tryptic peptides sequenced by tandem mass spectrometry. Fragmented peptide ions b+ and y+ are highlighted in red and blue
respectively.
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Agalychnis callidryas (ACKTI). In addition, the CCKP-1 mature
sequence showed 50% similarity with a number of trypsin
inhibitors from Fulmarus glacialis, Falco cherrug, Egretta garzetta,
and A. callidryas. These trypsin inhibitors have a characteristic
lysine (K) or arginine (R) in the P1 position and a proline (P) in the
P2 position of the active site. A trypsin inhibitory activity was
predicted for CCKP-1 because it also shared a lysine (K) in the
P1 position; but, in contrast, it had an asparagine (N) instead of
Proline (P) in the P2 position (Table 3). Moreover, CCKP-1 had a
similar secondary structure to the trypsin inhibitors of Salmo salar
Table 3
Comparison of CCKP-1 with other Kazal trypsin inhibitors according to BLAST/p (protein–protein blast).
Protein Sequ ence Ident ity Acces ion
* * * * * * * * * * * * * * * * * * * * % Number
Kazal protein Cruzioh yla 
calcarifer  1 CCKP -1 A V S A E C A R Y G - - L A C N K M L A P V C G T D G T T Y S N Q C M L C Y Y N R K N K K N I E I R S R G R C KX06506 0
Trypsin inh ibitor precursor 
Aga lychn is calli dryas A T K P R C - Q Y - - I V L C P R I L R P V C G T D G I T Y P N E C L L C Q S N R D D E K D V K I Q S Q G R C 52 CC F72386.1
Pan crea tic secretory 
trypsin inh ibitor precursor 
Salmo  salar A T E P D C S Q Y S - L P M C P R N F D P V C G S D G I T Y S N E C M L C F Q N M E W N T N I L I Q S K G E C 48 NP_001140094.1
PREDIC TED: trypsin 
inh ibitor ClTI-1-li ke pa rtial 
Fulma rus glaciali s - - - P A C Y K Y G - V P G C P R D Y N P V C G T D G E T Y S N E C V L C L S N S E N K K D V E I F K M G R C 55 XP_009582735.1
PREDIC TED: trypsin 
inh ibitor ClTI-1-li ke Falco 
cherr ug C P S P A C Y K Y G G V P G C P K D Y N P V C G T N G K T Y S N E C V L C F S N S E N K K N V Q I F K M G R C 53 XP_005436761.1
PREDIC TED: serine  
protea se inh ibitor Kazal-
type  2 Egrett a ga rzetta L Q Q P A C H R Y G - V P G C P R D Y N P V C G T D G H T Y S N E C V L C L S N S E N K K D V Q I F K M G R C 55 XP_009633154.1
Kazal patt ern C C P2 P1 X X X X X C X X X X X X Y X X X C X X C C
*Conserved sites, The Kazal motif is highlighted: 6 Cysteines are in yellow, one Tyrosine in pink, and P1 and P2 sites in red.
Fig. 7. Secondary structure prediction analysis of trypsin inhibitors using GOR IV method [22]. A) CCKP-1 Cruziohyla calcarifer Kazal Protein-1 Trypsin inhibitor. B) Pancreatic
secretory trypsin inhibitor of Salmo salar. C) Trypsin inhibitor of Sus scrofa.
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and Sus scrofa (Fig. 7). In addition, CCKP-1 was identiﬁed in the
archived fractions 32 and 33, from an HPLC fractionation
performed 15 years ago, due to their monoisotopic molecular
mass of 5926.43, as determined by MALDI-TOF MS analysis and
conﬁrmed by a LCQ ESI MS (Fig. 4). Additionally, trypsin inhibitory
activity was detected in those fractions conﬁrming the activity
prediction as is shown in Fig. 3.
The closest relatives of CCKP-2, based on their sequence
similarities, are the proteinase inhibitors PI01 and PI02 from
Phyllomedusa nordestina, and PSKP-1 and PSKP-2 from P. sauvagii.
PI01 and PI02 have proline in P2 position and leucine or valine in
position P1. However, PSKP-1 and PSKP-2 have two prolines in
positions P1 and P2 displaying a prolyl endopeptidase activity and
lacking any trypsin, chymotrypsin, V8-peptidase, and proteinase K
inhibitory activity. Moreover, trypsin inhibitor activity can be
acquired if the P1 Proline is changed for lysine. In contrast, CCKP-2
has a leucine in its P1 site and a proline in the P2 site of the active
site. CCKP-2 also showed 47–53% similarity with chymotrypsin
inhibitors from birds, such as Tinamus guttatus and Tauraco
erythrolophus, which have a leucine in P1 and proline in P2
position. In addition, CCKP-2 showed a similar secondary structure
to the chymotrypsin inhibitor of the penguin Pygoscelis adeliae
(Fig. 8). Due to these sequence similarities and secondary
structures, a chymotrypsin inhibitory activity is suspected for
CCKP-2.
In a similar way, CCKP5 and CCKP-7 displayed a high similarity
(64–81%) with the same peptidase inhibitors PI01, PI02 from
Phyllomedusa nordestina and PSKP-1 and PSKP-2 from P. sauvagii.
However, in contrast with CCKP-2, CCKP5 and CCKP-7 have an
aspartic acid in the P2 position instead of proline, but share the
Fig. 8. Secondary structure prediction of chymotrypsin inhibitors using GOR IV method [22]. A) CCKP-2 Cruziohyla calcarifer Kazal Protein-2. B) Cruziohyla calcarifer Kazal
Protein-5a) Cruziohyla calcarifer Kazal Protein-7a) Chymotrypsin inhibitor of Pygoscelis adeliae.
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leucine in P1 position. For this reason and their similarity to the
secondary structure of the chymotrypsin inhibitor of Pygoscelis
adeliae, especially in their N-terminal regions, it is presumed that
CCKP-5 and CCKP-7 also have chymotrypsin inhibitory activity
similar to CCKP-2 (Fig. 8).
In the same way, CCKP-4 has a lysine (K) in position P1 which
leads to a suspicion of trypsin inhibitory activity; but instead of the
P2 proline, present in most other trypsin inhibitors, CCKP-4 has a
serine (S). In addition, CCKP-4 showed an unusual 47% similarity to
the sperm-activation protein from the herring Clupea pallassi most
likely by sharing the Kazal motif rather than for a functional
relationship.
The other two proteins, CCKP-3 and CCKP-6, have a serine (S)
and an aspartic acid (D) respectively in their P1 positions. Their
sequences are similar to serine peptidase inhibitors in general, but
we cannot infer any speciﬁcity based on their P1 residues.
To conﬁrm the biological activity of CCKP-2 to CCKP-7, all
peptides should be identiﬁed in the individual fractions and tested.
Another option could be to overexpress the 5 proteins in
Escherichia coli, so that the puriﬁed proteins could be tested over
different peptidases to conﬁrm our predictions. Unfortunately, the
scarce material available did not allow the protein identiﬁcation in
the individual fractions. However, their primary structures were
100% conﬁrmed by LCQ MS/MS sequencing employing the whole
secretion of 13 individual samples including wild and captive frogs
from different sources. It is noticeable, that differential expression
was observed in the 12 Costa Rican samples in spite of being
analysed at the same concentration (1 mg/mL). Would be
interesting to test in the future how the developmental stages
(juvenile vs. adults), habitats, and distributions affect the expres-
sion of these protease inhibitors.
In contrast with other species, Cruziohyla calcarifer has proven
to be a rich source of Kazal-type proteins with proven trypsin
inhibitor activity in at least one of them, and predicted trypsin and
chymotrypsin inhibitory activity in some others. Moreover, their
extraordinary diversity contains 2 Kazal-type proteins that show
unusual P1 and P2 residues which preclude their activity
prediction. The biological role of those inhibitors is uncertain;
however, they probably regulate the balance of antimicrobial and
other bioactive peptides on the skin surface of the frogs, to protect
them against pathogenic microorganisms and predators. The
extraordinary diversity of these Kazal-type protein inhibitors in
the skin of C. calcarifer possibly mirrors the complexity of peptides
and proteins still unknown in other species, and promotes research
on this species in particular.
5. Conclusions
In conclusion, the combined strategy including tandem mass
sequencing, molecular cloning and HPLC fragmentation allowed
the identiﬁcation of 18 variants of Kazal-type proteins of Cruziohyla
calcarifer (CCKP). These proteins were classiﬁed in 7 types by
sequence similarity. CCKP-1 and 4 were deemed of trypsin
inhibitory activity while CCKP-2, 5, 7 were deemed of chymotryp-
sin inhibitory activity by sequence homology with other peptidase
inhibitors. In addition, CCKP-1 was identiﬁed in the chro-
matographic fraction No.32 showing trypsin inhibitory activity
and a molecular mass of [M+H]+ = 5926.43 Da. In this way, C.
calcarifer has showed to be an important source of diverse
peptidase inhibitors promoting further research of the skin
secretions in this species.
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